Pfizer-BioNTech Evaluating Third COVID-19 Vaccine Dose for Variants
The new trial comes at a time when the FDA has provided guidance on navigating immunogenicity trials for vaccines designed against more transmissible SARS-CoV-2 strains.
Related Articles
IDWeek 2024 Review: Shionogi’s Antibiotic for Use in Adults with Certain Gram-negative Bacterial Infections
Contagion® is a news resource for infectious disease specialists and practitioners, aiding identification, diagnosis, treatment and prevention.
TAXIS Pharmaceuticals Earns FDA QIDP Designation For its Efflux Pump Inhibitor For Pneumonia
The designation is for the company’s, TXA14007, its investigational antibiotic to be studied in combination with levofloxacin.
Screening Study For Hepatitis B Shows Nearly 1/3 Also has Hepatitis D
In our latest podcast, first author Elizabeth Marlowe, PhD, D (ABMM), offers insights on her study looking at this ongoing issue including the need for…
Merck’s MK-8527 Advances to Phase 3 for Once-Monthly HIV Prevention
At IAS 2025, Luisa Stamm, MD, PhD, explains the NRTTI’s mechanism, study setup, and key data on HIV prevention efforts.
A Group of Antimicrobial Compounds Show Novelty Action Against Multidrug-Resistant Gonorrhea
TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, discusses dihydrofolate reductase inhibitors (DHFRIs) as a novel approach to combat resistant neisseria gonorrhoeae.
Long-Acting HIV Therapy Gains Ground in Both New and Experienced Patients
At IAS 2025, the VOLITION and OPERA study data presented at IAS 2025 show patient preference and real-world use of injectable CAB + RPV LA,…
FDA Accepts New Drug Application for Merck’s HIV Treatment, Doravirine/Islatravir
This investigational two-drug regimen for treatment of adults with virologically suppressed HIV was given a Prescription Drug User Fee Act (PDUFA) date of April 28,…
Frequent Hepatitis C Testing Among PWID Found to Be Cost-Effective, Study Finds
Study findings underscore the cost-effectiveness of more frequent hepatitis C testing among people who inject drugs, compared to less frequent or no testing at all.
Quickening a Rapid HCV Test Reduces True and False Positives
Shortening the OraQuick HCV antibody test from 20 to 5 minutes reduced false positives and unnecessary follow-up RNA testing, but detected fewer viremic individuals.
Top 5 Infectious Disease News Stories Week of July 5-12
Contagion® is a news resource for infectious disease specialists and practitioners, aiding identification, diagnosis, treatment and prevention.